FDA Clearance Tracker · P150004-S033
Proclaim DRG IPG
Last checked: Nov 20, 2026Latest source record: Jun 5, 2020 (this decision)Source: openFDAMethods & limitations
Decided
Jun 5, 2020
Approved
Time to decision
210 days
Received Nov 8, 2019. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track
Device class
Class III
The decision
- FDA number
- P150004-S033
- Device name
- Proclaim DRG IPG
- Applicant
- ABBOTT MEDICAL
- Applicant location
- Plano, TX
- Received
- Nov 8, 2019
- Decided
- Jun 5, 2020
- Decision
- Approved
- Supplement type
- Normal 180 Day Track
- Reason for supplement
- Change Design/Components/Specifications/Material
- Original approval
- P150004
Device type
- Device class
- Class III
FDA's approval statement
As written in FDA's record.
Approval for cybersecurity software updates for the Clinician Programmer (CP) and Patient Controller (PC).
Source documents
Other decisions for ABBOTT MEDICAL
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
P260019 · Decided Oct 27, 2026 · 180 days after receipt
Device type: Para-device leak occluder (SJT) · Cardiology
- EnSite X EP System510(k)
K261729 · Decided Sep 17, 2026 · 114 days after receipt
Device type: Computer, Diagnostic, Programmable (DQK) · Cardiology
- TactiFlex Duo Ablation Catheter, Sensor Enabled (A-TFDM-D, A-TFDM-F, A-TFDM-J, A-TFDM-DD, A-TFDM-DF, A-TFDM-FF, A-TFDMPMA supplement
P220013-S028 · Decided Sep 4, 2026 · 186 days after receipt · Panel Track
Device type: Catheter, percutaneous, cardiac ablation, for treatment of atrial fibrillation (OAE) · Cardiology
5 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.